About Moderna
Moderna is a publicly listed company based in Cambridge (United States) founded in 2010 by Robert S Langer, Kenneth R Chien, and Timothy A Springer. MRNA-based therapeutics for diseases including cancer and infections are developed. It operates on a HealthTech model. Moderna has raised $2.78 billion across 21 funding rounds from investors including Merck, Fidelity Investments and Astrazeneca. The company has 5,800 employees. Moderna has completed 1 acquisition, including OriCiro Genomics. Its website modernatx.com draws about 206 thousand monthly visits. Moderna offers products and services including mRNA Medicines. Its focus areas include Biotechnology and mRNA Technology. Its legal entity is Moderna, Inc. Its competitors include BridgeBio, Adaptive Biotechnologies and Spark Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Moderna is engaged in pioneering mRNA technology to create medicines that combat diseases by instructing cells to produce necessary proteins. The company operates in the biotechnology sector, targeting a wide range of conditions, including those with no current treatments. Solutions are designed to be accessible, free of animal products or preservatives, and are developed rapidly through a unique platform that allows multiple mRNA designs to be tested efficiently. Efforts are made to deliver impactful health solutions globally.
- Headquarters Cambridge, United States
- Employees 5,800
- Founders Robert S Langer, Kenneth R Chien, Timothy A Springer
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website modernatx.com/en-US
- Social LinkedIn X Facebook Instagram
- Legal Name Moderna, Inc.
- Annual Revenue$1.94 B (USD)-39.93as on Dec 31, 2025
- Net Profit-$2.82 B (USD)20.75as on Dec 31, 2025
- EBITDA-$2.86 B (USD)23.88as on Dec 31, 2025
- Total Equity Funding$2.78B (USD)
in 21 rounds
- Latest Funding Round$590M (USD), Grant
Jan 2025
- InvestorsMerck
& 21 more
- Employee Count5,800
- Investments & Acquisitions
Products & Services of Moderna
Moderna offers a comprehensive portfolio of products and services, including mRNA Medicines.
mRNA medicines are developed to fight various diseases.
Funding Insights of Moderna
Moderna has successfully raised a total of $2.78B across 21 strategic funding rounds. The most recent funding activity was a Grant round of $590 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.78B
- Total Rounds 21
- Last Round Grant — $590M
- First Round $40M
(Nov 2012)
- Investors Count 22
Latest 10 of 21 funding rounds of Moderna with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2025 | $590M | Grant | – | HHS | – |
| Jul 2024 | $176M | Grant | – | HHS | – |
| Oct 2020 | $56M | Grant | – | – | |
| May 2020 | Post-IPO | – | – | – | |
| Apr 2020 | $483M | Grant | – | – | |
| May 2018 | $125M | Series G | – | Merck | – |
| Feb 2018 | $500M | Series G | – | ADIA, BB Biotech | |
| Sep 2016 | $8M | Grant | – | – | – |
| Sep 2016 | $474M | Series F | – | – | – |
| Aug 2016 | $600M | Series E | – | – | – |
22 investors in total: 22 institutional.
Investors in Moderna
Moderna has secured backing from 22 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Fidelity Investments and Astrazeneca.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
PE firm investing in Asia and Europe | 1993 | bbbiotech.ch | Schaffhausen, Switzerland | |
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Early stage investments focused VC firm | acks.com | |||
Government-backed investments are directed toward healthcare, fintech, and various sectors. | edbi.com | Singapore, Singapore | ||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| 1958 | darpa.mil | United States | ||
| phe.gov |
Investor details for Moderna
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Moderna
814 people are tracked at Moderna (369 in leadership, 8 in board & advisors, 437 in team); the tracked headcount is 5,800.
| Name | Role | Group |
|---|---|---|
Robert S Langer | Co-Founder | Leadership |
Kenneth R Chien | Co-Founder | Leadership |
Timothy A Springer | Co-Founder | Leadership |
Rebecca Diemand | Director, Facilities & Engineering | Leadership |
Maxim Sheinin | Senior Director, Strategic Forecasting | Leadership |
Leo Bedard | Associate Director Capital Projects | Leadership |
Shannon Thyme Klinger | Chief Legal Officer & Corporate Secretary | Leadership |
Sangpyo Kim | General Manager | Leadership |
Don Parsons | Head, Early Technical Development And LNP Process Development | Leadership |
Gabor Szetey | Vice President Human Resources R&d | Leadership |
Pratima Tothempudi | Director, HR Business Partner CMC At Moderna | Leadership |
Jamie Kinch | Vice President, Real Estate And Corporate Facilities | Leadership |
Pradeep Reddy | Associate Scientific Director | Leadership |
Emily Fullerton | Director, Product Quality Lead | Leadership |
Conor Knightly | Vice President, Clinical Operations, Infectious Disease | Leadership |
Ivonne Amaral | Cost Accounting Director | Leadership |
Marcus Sinha | Sr. Director Data Protection And European Data Protection Officer | Leadership |
Wen-Han Yu | Director, Computational Immunology | Leadership |
Scott Nickerson | Senior Vice President, Individualized Neoantigen Therapy Manufacturing | Leadership |
Sinead Rainville | Vice President Of Quality, INT | Leadership |
794 more people are available in the full profile.
Complete people profiles for Moderna
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Moderna
Moderna is a publicly listed company on the NASDAQ with ticker symbol MRNA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Oct 2020
- Listed onB3: M1RN34
- Listed entityModerna, Inc.
- Exchange sectorHealth technology
- ISINUS60770K1079
- Share price$216.25 (+1.17% on the day) · 2026-10-13
- Market capitalisation$86.33B
- EPS (diluted, trailing year)$-7.98
- Volume (last session)13,389,241
Financials of Moderna
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.94B | -$2.82B | -$2.86B |
| 2024 | $3.24B | -$3.56B | -$3.76B |
| 2023 | $6.84B | -$4.71B | -$3.63B |
| 2022 | $19.11B | $8.36B | $9.61B |
| 2021 | $18.41B | $12.20B | $13.47B |
Detailed financial statements for Moderna
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Moderna
Moderna has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include OriCiro Genomics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Technologies for DNA synthesis and amplification are developed. | oriciro.com | Tokyo, Japan | 2018 | Jan 2023 | $85M |
Complete acquisition details for Moderna
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Moderna
5 dated milestones of Moderna across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Moderna is founded.
- Funding First funding round of $40.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires OriCiro Genomics.
- Funding Latest funding round, Grant, of $590.0M.
Competitors of Moderna
Moderna has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Adaptive Biotechnologies and Spark Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. |
Detailed competitors of Moderna
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Moderna
The website of Moderna (modernatx.com) receives about 205.5K visits a month and ranks #175,609 among all websites worldwide, #5,568 in Biotechnology and Pharmaceuticals.
- Monthly visits205.5K
▼ 22.2% vs previous month
- Unique visitors134.5K
per month
- Global rank#175,609
among all websites
- Category rank#5,568
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.4
- Average visit1 min 02 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Moderna. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pfizer.com | 100% | 1.9M | #24,984 | View details | |
modernatherapeutics.sharepoint.com | modernatherapeutics.sharepoint.com | 98% | – | ||
careers.lilly.com | careers.lilly.com | 87% | #60,411 | – | |
| vrtx.com | 85% | 342.2K | #151,023 | View details | |
| novartis.com | 85% | 948.8K | #58,822 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Moderna
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Moderna (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Moderna
Complete news archive for Moderna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Moderna
Moderna was founded in 2010 and raised its 1st funding round 2 years after it was founded.
Moderna is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Moderna is a funded company, having raised a total of $2.78B across 21 funding rounds to date. The company's 1st funding round was a Series E of $600M, raised on Nov 2012.
Moderna has 5,800 employees.
Annual revenue of Moderna is $1.94B as on Dec 31, 2025.
Moderna is engaged in pioneering mRNA technology to create medicines that combat diseases by instructing cells to produce necessary proteins. The company operates in the biotechnology sector, targeting a wide range of conditions, including those with no current treatments. Solutions are designed to be accessible, free of animal products or preservatives, and are developed rapidly through a unique platform that allows multiple mRNA designs to be tested efficiently. Efforts are made to deliver impactful health solutions globally.
Moderna's top competitors include Spark Therapeutics, BridgeBio and Adaptive Biotechnologies.
Moderna offers mRNA Medicines.
Yes, Moderna is publicly traded on NASDAQ under the ticker symbol MRNA.
Moderna has made 1 acquisition, including OriCiro Genomics.
Moderna has 22 investors. Key investors include Merck, Fidelity Investments, Astrazeneca, Alexion, and Julius Baer.
Moderna operates through Moderna, Inc..